Gustafsson H, Kale A, Dasu A, Lund A, Edqvist P-H, Roberg K
Department of Radiology Norrköping and Department of Medical and Health Sciences (IMH), Linköping University, Linköping, Sweden.
Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden.
Cell Biochem Biophys. 2017 Dec;75(3-4):299-309. doi: 10.1007/s12013-017-0814-5. Epub 2017 Jul 29.
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on female BALB/c (nu/nu) nude mice. Mice with xenografts were given three injections of intraperitoneal cetuximab or phosphate-buffered saline, and the tumour volume was recorded continuously. After treatment the tumour partial oxygen pressure was measured by LiPc electron paramagnetic resonance oximetry and the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, Ki-67, MCT1, MCT4, GLUT1, CAIX and HIF-1α were investigated by immunohistochemistry. In xenografts from both cell lines (UT-SCC-2 and UT-SCC-14) cetuximab had effect on the tumour volume but the effect was more pronounced on UT-SCC-14 xenografts. A higher tumour oxygenation was measured in cetuximab-treated tumours from both cell lines compared to untreated controls. Immunocytochemical staining after cetuximab treatment shows a significantly decreased expression of EGFR, pEGFR, Ki67, CAIX and nuclear HIF-1α in UT-SCC-14 tumours compared to untreated controls. MCT1 and GLUT1 were significantly decreased in tumours from both cell lines but more pronounced in UT-SCC-14 tumours. Taken together, our results show that cetuximab treatment decreases the tumour growth and increases the tumour partial oxygen pressure of HNSCC xenografts. Furthermore we found a potential connection between the partial oxygen pressure of the tumours and the expression of proteins involved in tumour growth, metabolism and hypoxia.
尽管治疗方法有所进步,但头颈部鳞状细胞癌(HNSCC)肿瘤的死亡率仍然很高。单克隆抗体西妥昔单抗(爱必妥)已被批准用于治疗晚期HNSCC。然而,接受西妥昔单抗治疗的HNSC患者中只有一部分实际对治疗有反应,这突出表明需要一种方法来为个体患者量身定制治疗方案。本研究的目的是调查西妥昔单抗治疗对肿瘤生长、通过脂质体电子顺磁共振血氧测定法测量的肿瘤局部氧分压以及参与肿瘤生长、代谢和缺氧的蛋白质表达的影响。使用两种HNSCC细胞系UT - SCC - 2和UT - SCC - 14在雌性BALB/c(nu/nu)裸鼠上生成异种移植瘤。给患有异种移植瘤的小鼠腹腔注射三次西妥昔单抗或磷酸盐缓冲盐水,并连续记录肿瘤体积。治疗后,通过脂质体电子顺磁共振血氧测定法测量肿瘤局部氧分压,并通过免疫组织化学研究表皮生长因子受体(EGFR)、磷酸化EGFR、Ki - 67、MCT1、MCT4、GLUT1、CAIX和HIF - 1α的表达。在来自两种细胞系(UT - SCC - 2和UT - SCC - 14)的异种移植瘤中,西妥昔单抗对肿瘤体积有影响,但对UT - SCC - 14异种移植瘤的影响更明显。与未治疗的对照组相比,在来自两种细胞系的经西妥昔单抗治疗的肿瘤中测量到更高的肿瘤氧合。与未治疗的对照组相比,西妥昔单抗治疗后的免疫细胞化学染色显示UT - SCC - 14肿瘤中EGFR、pEGFR、Ki67、CAIX和核HIF - 1α的表达显著降低。两种细胞系肿瘤中的MCT1和GLUT1均显著降低,但在UT - SCC - 14肿瘤中更明显。综上所述,我们的结果表明西妥昔单抗治疗可降低HNSCC异种移植瘤的肿瘤生长并增加其肿瘤局部氧分压。此外,我们发现肿瘤的局部氧分压与参与肿瘤生长、代谢和缺氧的蛋白质表达之间存在潜在联系。